Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2006

View Archived Issues

Targeting IGF-1R shows antitumor efficacy in mouse models of lung cancer

Ruboxistaurin reduces the risk of vision loss in diabetic retinopathy

Licorice component protects mice against DMN-induced lung and colon tumors

Efficacy of targeting the adenosine A3 receptor shown in patients with rheumatoid arthritis

Targets in nephrology

Novel preclinical data on Zyflamend's antitumor mechanism

Davanat studied in phase II first-line colorectal cancer study

GV-1001 begins phase II trial in liver cancer

FDA accepts complete response for Factive in five-day treatment of CAP

QSC-001 begins clinical program

Kamada begins phase I trials with inhaled API product for congenital emphysema

Neose receives milestone payment under Factor VIIa agreement with Novo Nordisk

Biota and Boehringer Ingelheim enter HCV licensing agreement

First generic ondansetron injection products approved in U.S.

Lundbeck and Biotie sign agreement for nalmefene

Novartis presents pipeline review

No reported increase in Tamiflu resistance

Cytokinetics and GSK amend license and collaboration agreement

Biocon working towards launch of antiarthritis drug in India

New pivotal study begins for Clolar in adult AML

Enrollment complete in phase II trial of MitoQ in Parkinson's disease

Sankyo patents novel compounds for transplant rejection, autoimmune diseases, etc.

Novel Rho kinase inhibitors revealed in D. Western Therapeutics patents

TRK-820 filed in Japan for severe uremic pruritus in hemodialysis patients

Recent patents disclose novel agents with potential in the treatment of HCV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...